Health Initiatives in Psoriasis and Psoriatic Arthritis Consortium European States (HIPPOCRATES)

01 July 2021


Promoting Early Identification and Improving Outcomes in Psoriatic Arthritis

Psoriatic arthritis affects at least 30% of people living with psoriasis and is associated with an increased risk of other comorbidities.

The Health Initiatives in Psoriasis and Psoriatic Arthritis Consortium European States (HIPPOCRATES) is a study that will enhance the quality of life of persons living with Psoriatic Arthritis (PsA). Launched on July 1st, 2021, this initiative is a collaboration between European research partners, pharmaceutical companies, SME’s and patient organizations.

The objectives of the HIPPOCRATES are to identify early patients at risk of progression to PsA in order to enable early intervention and prevention. In addition, the initiative aims to define factors that can predict bone/joint damages early. This would support the development of more adapted and personalized treatment strategies with optimized outcomes.

The project includes an integrated approach of patient involvement in the overall consortium with active consultation of people living with Psoriatic disease. Three patient organizations are taking part in the consortium as collaborative or associated partners these include: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), PARE (Persons with Arthritis and Rheumatism in Europe)- EULAR, and EUROPSO (European Federation of psoriasis patients' association) led by president, Jan Koren (Slovenia) David Trigos (vice-president) and Lars Werner (CEO Danish Psoriasis Association)

The 5-year project will revolutionize treatment and deliver profound patient benefits.

IFPA recognizes the HIPPOCRATES project and encourages networks in the study region to inform networks and communities about this worthwhile initiative. We look forward to the outcomes of the project development of innovative, personalized treatment options for people affected by psoriatic arthritis which will be of benefit to the estimated 60 people living with psoriasis worldwide.

Read more: